Amedisys Reports First Quarter 2018 Financial Results and Reaffirms 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Amedisys (AMED) Tops Q1 EPS by 12c, Offers FY Guidance
May 7, 2018 5:01 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $399.3 million versus the consensus estimate of $395.28 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, versus the consensus of $3.00. Amedisys sees... More



